Cardinal Health
CAH
$283.85
+0.98%
Cardinal Health, Inc. is one of the three dominant U.S. pharmaceutical wholesalers, sourcing and distributing branded, generic, and specialty drugs to retail chains, independent pharmacies, hospital networks, and healthcare providers, while also supplying medical-surgical products and equipment across North America, Europe, and Asia. Alongside Cencora and McKesson, it controls well over 90% of the U.S. pharmaceutical wholesale market, giving it an oligopolistic position defined by scale, distribution density, and deep manufacturer relationships rather than pricing power. The current investor narrative centers on the durability of that model: a strong fiscal Q1 2027 print, raised full-year guidance, long-term CVS contract renewal, and accelerating specialty-pharmaceutical growth have driven the stock to fresh highs and reframed CAH from a low-margin value name into a steady compounder. Debate now hinges on whether generics-driven profit growth (management guides Pharma segment profit growth of 8-11% for fiscal 2027) and specialty mix can sustain the re-rating, or whether the razor-thin margin structure leaves the stock vulnerable to any revenue miss, as seen when a prior quarter's top-line shortfall briefly sank the shares.…
CAH
Cardinal Health
$283.85
Related headlines
Investment Opinion: Should I buy CAH Today?
Rating: Hold (accumulate on pullback). The core thesis is that Cardinal Health has genuinely transformed from a low-margin value name into a steady, cash-generative compounder — Q1 fiscal 2027 EPS of $2.39 rose 26% year-over-year on 5.47% revenue growth, management raised full-year guidance, and the long-term CVS renewal removed the biggest overhang — but at $281.10 the stock already trades at roughly 95.4% of its 52-week range and offers only ~4.9% upside to the $294.87 average analyst target, so the risk/reward favors patience rather than chasing. The 14 Buy / 3 Hold / 0 Sell consensus (recommendation mean 1.53) confirms durable conviction in the business, not necessarily in the entry price.
Supporting evidence is strong on fundamentals: trailing-twelve-month free cash flow of $4.90 billion against Q1 operating cash flow of $1.398 billion and capex of just $157 million funded $500 million of buybacks and $126 million of dividends internally; gross margin expanded to 3.85% from 3.62% a year ago, lifting net income to $554 million from $450 million; and the forward PE of 19.55x on consensus EPS of $20.68 is moderate for a business guiding 8-11% Pharma segment profit growth, even though the trailing PE of 32.68x and PEG of 2.68 sit in the upper historical band. Price-to-sales of 0.22x is near the low end of its historical 0.30-0.88x range, so the premium is earnings-driven rather than sales-multiple inflation, and beta of 0.521 with +24.15% relative strength versus SPY confirms the 36.42% one-year gain is idiosyncratic and catalyst-driven.
The biggest risks that could invalidate the thesis are a revenue miss against the razor-thin 1.12% operating margin (the stock previously sank on exactly such a quarter despite an earnings beat and raised outlook), a de-rating of the 32.68x trailing PE toward the mid-teens if specialty growth stalls below the 8-11% guide, and competitive pressure from Cencora and McKesson, which together with CAH hold over 90% of U.S. wholesale. This Hold would upgrade to Buy on a pullback toward the $250-$254 consolidation floor (implying roughly 15-17x forward EPS and ~15% upside to the average target) or on evidence that specialty mix is accelerating segment profit growth above 11%; it would downgrade to Sell if revenue growth decelerates below ~3% or gross margin slips back toward the 3.38% Q2 2026 trough. Net verdict: fairly valued to modestly rich relative to its own history, but reasonably priced on forward earnings — a high-quality business at a full price.
Sign up to view all
CAH 12-Month Price Forecast
The forward view is balanced: the business is executing well — 26% EPS growth on 5.47% revenue growth, raised guidance, a long-term CVS renewal, and $4.90 billion of TTM free cash flow — but the stock has already re-rated 36.42% over one year and sits just 1.8% below its $286.29 52-week high, leaving only ~4.9% to the average target. The 19.55x forward PE is defensible if $20.68 of EPS is delivered, but the 32.68x trailing multiple and 2.68 PEG mean any deceleration would compress the multiple toward the $260 bear target. With beta of 0.521 and +24.15% relative strength versus SPY, the rally is company-specific and fundamentally driven rather than beta-fueled, which supports holding through volatility but argues against adding at current levels. I would upgrade to bullish on a pullback into the $250-$254 consolidation zone or on evidence that specialty mix is pushing segment profit growth above the 11% high end of guidance; I would downgrade to bearish if revenue growth slips below ~3% or gross margin breaks below 3.6%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cardinal Health's 12-month outlook, with a consensus price target around $294.87 and implied upside of +3.9% versus the current price.
Average Target
$294.87
17 analysts
Implied Upside
+3.9%
vs. current price
Analyst Count
17
covering this stock
Price Range
$260 - $330
Analyst target range
Coverage is solid, with 15 analysts and a clearly bullish tilt: 14 Buy ratings, 3 Hold, and 0 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.53 (where 1.0 is a strong buy). The average target price of $294.87 implies roughly +4.9% upside from the current $281.10, a modest gap that suggests much of the good news is already reflected after the stock's 36% one-year run. The consensus leans bullish on direction but cautious on near-term upside, consistent with a stock trading near its 52-week high.
The target range of $260 to $330 is moderately wide, spanning about 27% from low to high, which signals meaningful dispersion in assumptions. The $330 high target likely assumes accelerating specialty growth, successful CVS contract execution, and further multiple expansion toward the mid-20s forward PE, while the $260 low target prices in margin compression or a revenue-driven de-rating like the one that hit the stock after a prior top-line miss. Institutional ratings show a stable-to-positive pattern, with recent reiterations from Argus (Buy), TD Cowen (Buy), Evercore ISI (Outperform), RBC (Outperform), Morgan Stanley (Overweight), UBS (Buy), and Mizuho (Outperform), and only JP Morgan holding a Neutral stance; the absence of downgrades and the 14-to-3 buy/hold split indicate durable conviction, though the tight ~5% average upside argues for patience on entry rather than chasing at current levels.
Bulls vs Bears: CAH Investment Factors
The bull case currently holds stronger evidence: a raised fiscal 2027 outlook, an 8-11% Pharma segment profit growth guide, a long-term CVS renewal, $4.90 billion of TTM free cash flow, and 26% EPS growth on 5.47% revenue growth all point to a durable, cash-generative compounder. The bear case is primarily about price rather than business quality — only ~4.9% upside to the $294.87 average target, a 32.68x trailing PE in the upper historical band, and a 1.12% operating margin that leaves no room for a revenue miss. The single most important tension is whether specialty mix and generics profitability can sustain the re-rating long enough for forward earnings to catch up to the trailing multiple; if forward EPS of $20.68 delivers, the 19.55x forward PE is defensible, but any top-line shortfall would likely compress the multiple toward the low-$260s bear target. With beta of 0.521 and relative strength of +24.15% versus SPY, the rally is company-specific and fundamentally driven, but the risk/reward at $281.10 is asymmetric toward patience rather than chasing.
Bullish
- Raised guidance and CVS renewal de-risk growth: Management raised full-year fiscal 2027 guidance and secured a long-term CVS contract renewal, removing the single largest customer-renewal overhang that had capped the multiple. Management now guides Pharma segment profit growth of 8-11% for fiscal 2027, a visible earnings runway that supports the re-rating from value name to compounder.
- Free cash flow of $4.9B dwarfs net income: TTM free cash flow of $4.90 billion versus Q1 2027 net income of $554 million reflects the working-capital dynamics of a high-turnover distributor. Q1 operating cash flow of $1.398 billion against just $157 million of capex funded $500 million of buybacks and $126 million of dividends internally, with no need for external capital.
- Earnings inflecting faster than revenue: Q1 2027 EPS of $2.39 rose from $1.89 a year earlier (+26%), well ahead of the 5.47% revenue growth to $67.51 billion, as gross margin expanded to 3.85% from 3.62%. Net income of $554 million versus $450 million a year ago confirms operating leverage is flowing through despite the thin 1.12% operating margin.
- Forward PE of 19.5x is reasonable for the growth: The trailing PE of 32.68x looks rich, but the forward PE of 19.55x on consensus EPS of $20.68 is moderate for a business compounding segment profit at 8-11%. Price-to-sales of 0.22x sits near the low end of its historical 0.30-0.88x range, so the premium is earnings-driven, not sales-multiple inflation.
Bearish
- Only ~5% upside left to consensus target: The average analyst target of $294.87 implies just +4.9% upside from $281.10, and the stock already trades at roughly 95.4% of its 52-week range of $180.45-$286.29. With 14 Buy ratings already in place, there is little room for positive estimate revisions to drive further multiple expansion from here.
- Razor-thin 1.12% operating margin leaves no cushion: Operating income of $753 million on $67.51 billion of revenue yields a 1.12% operating margin, and the 3.85% gross margin means a small mix shift or pricing concession can erase a large share of profit. The stock previously sank after a single quarterly revenue shortfall that overshadowed an earnings beat and raised outlook, showing how fragile sentiment is to top-line misses.
- Trailing PE of 32.7x sits in upper historical band: The 32.68x trailing PE is well above the ~16-18x seen in 2024 and early 2025, placing it in the upper portion of its historical range. A PEG ratio of 2.68 signals the market is paying more than 2.5x growth for the earnings stream, leaving the stock exposed to de-rating if growth decelerates.
- Near-parabolic momentum invites consolidation: The stock rose from ~$254 on November 2 to $281.10 on November 13, up 13.47% in one month and 44.01% over six months, a vertical move that historically precedes consolidation. Resistance at the $286.29 52-week high is only 1.8% away, and a failure there could trigger profit-taking toward the $250-$254 consolidation floor.
CAH Technical Analysis
CAH is in a powerful, sustained uptrend, with the stock up 36.42% over the past year and 36.64% year-to-date, and the current price of $281.10 sits at roughly 95.4% of its 52-week range of $180.45 to $286.29. That positioning near the top of the range signals strong momentum rather than a value opportunity, though it also raises the risk of overextension after a near-parabolic run. The stock has decisively outperformed the market, with relative strength of +24.15% versus SPY over one year and +26.02% YTD, confirming leadership rather than a beta-driven rally.
Short-term momentum is accelerating rather than fading: the stock is up 13.47% over the past month and 19.53% over three months, both well ahead of the 36.42% one-year gain's implied pace, and the 6-month change of 44.01% shows the move is broadening. Critically, this strength is diverging sharply from a weak tape, with SPY down 2.26% over one month and 2.83% over three months, producing relative strength of +15.73% and +22.36% over those windows. That kind of counter-trend outperformance typically reflects fundamental catalysts (the raised outlook and CVS renewal) rather than a temporary mean-reversion bounce, though the recent vertical move from ~$254 on November 2 to $281.10 on November 13 argues for some near-term consolidation risk.
Key technical support sits at the 52-week low of $180.45, with a more relevant intermediate floor in the $250-$254 area where the stock consolidated in late October; resistance is effectively the 52-week high of $286.29, just 1.8% above the current price. A breakout above $286 would confirm the uptrend and likely invite momentum buyers, while a breakdown below $250 would signal the first meaningful trend crack after a 44% six-month run. The stock's beta of 0.521 means it is roughly half as volatile as the market, which is unusual for a name near highs and implies the rally is being driven by idiosyncratic, company-specific factors; combined with a short ratio of 4.5 days and a max drawdown of -20.61%, risk management should focus on position sizing around the $250 support rather than broad market hedging.
Beta
0.52
0.52x market volatility
Max Drawdown
-20.6%
Largest decline past year
52-Week Range
$180-$286
Price range past year
Annual Return
+38.2%
Cumulative gain past year
| Period | CAH Return | S&P 500 |
|---|---|---|
| 1m | +11.7% | -3.0% |
| 3m | +20.8% | -3.6% |
| 6m | +42.5% | -0.2% |
| 1y | +38.2% | +10.1% |
| ytd | +38.0% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAH Fundamental Analysis
Revenue is growing at a healthy clip for a distributor: fiscal Q1 2027 (quarter ended September 30, 2026) revenue reached $67.51 billion, up 5.47% year-over-year from $64.01 billion, and the multi-quarter trend is constructive, with revenue rising from $60.94 billion in Q3 2026 to $63.86 billion in Q4 2026 and now $67.51 billion. The Pharmaceutical segment dominates at $62.58 billion, dwarfing GMPD at $3.19 billion and other operations at $1.76 billion, so overall growth is essentially a function of drug distribution volume and specialty mix. The 5.47% top-line growth, paired with management's raised outlook and 8-11% Pharma segment profit growth guidance, supports the thesis that this is durable, volume-led expansion rather than a one-off.
Profitability is thin but improving: Q1 2027 net income was $554 million on a gross margin of 3.85% ($2.596 billion gross profit), and operating income of $753 million translated to an operating margin of just 1.12%, consistent with the low-margin wholesale model. Margins have been volatile quarter to quarter, with gross margin ranging from 3.38% in Q2 2026 to 4.30% in Q4 2026, but the current 3.85% is above the 3.62% posted in the year-ago Q1, and net income of $554 million compares favorably to $450 million a year earlier. The reported ROE of -59.45% and negative book value are artifacts of an aggressive buyback program that has driven shareholders' equity negative, not signs of operating distress, and the 3.72% ROA is the more meaningful profitability gauge for this capital-light, high-turnover business.
Cash generation is the standout: trailing-twelve-month free cash flow is $4.90 billion, Q1 2027 operating cash flow was $1.398 billion against capex of just $157 million, and the company returned capital via $500 million of buybacks and $126 million of dividends in the quarter. Liquidity is tight on a current-ratio basis at 0.88, but that is normal for distributors that run negative working capital, and the negative debt-to-equity of -3.45 reflects the equity deficit rather than excessive leverage. With a dividend yield of 0.88% and a low payout ratio of 28.6%, CAH retains ample flexibility to fund growth, bolt-on acquisitions ($149 million in Q1), and continued repurchases internally, which materially lowers financial risk despite the optically alarming balance-sheet ratios.
Quarterly Revenue
$67.5B
2026-09
Revenue YoY Growth
+5.5%
YoY Comparison
Gross Margin
3.9%
Latest Quarter
Free Cash Flow
$4.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAH Overvalued?
Because net income is positive ($554 million in Q1 2027), the PE ratio is the appropriate primary metric, and CAH trades at a trailing PE of 32.68x versus a forward PE of 19.55x. That wide gap implies the market expects substantial earnings growth, consistent with consensus EPS estimates of $20.68 for the forward period, and the forward multiple of ~19.5x is far more reasonable than the trailing figure suggests. The PEG ratio of 2.68 and price-to-cash-flow of 10.84x round out a picture of a stock priced for steady, not explosive, compounding.
On a peer basis, CAH's 0.22x price-to-sales and 0.27x EV/sales are typical of low-margin distributors, but its 17.58x EV/EBITDA and 32.68x trailing PE sit at a premium to the historical distribution-sector norm, reflecting the market's willingness to pay up for the specialty-growth and CVS-renewal story. The 3.85% gross margin and 0.67% net margin are structurally thin, so sales-based multiples flatter the stock while earnings-based multiples reveal the premium; the 19.55x forward PE is the fairest read and suggests the premium is moderate rather than extreme, justified by the 5.47% revenue growth and 8-11% segment profit growth guidance.
Historically, CAH's PE has ranged from the low teens to the 40s, and the current 32.68x trailing PE sits in the upper portion of that band, well above the ~16-18x seen in 2024 and early 2025 but below the 42x spike in mid-2025. The price-to-sales ratio of 0.22x, by contrast, is near the low end of its historical 0.30-0.88x range, a divergence that reflects margin expansion and buyback-driven EPS growth rather than multiple inflation on sales. Net-net, the stock is priced for optimism on earnings but not stretched on revenue, leaving room for further re-rating if specialty growth and generics profitability deliver.
PE
32.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 14x~42x
vs. Industry Avg
26.2x
Industry PE ~26.2x*
EV/EBITDA
17.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the extreme thinness of the margin structure: Q1 2027 operating income of $753 million on $67.51 billion of revenue is a 1.12% operating margin, and gross margin of 3.85% means a modest pricing concession or generic deflation could erase a meaningful share of profit. Revenue concentration is acute, with the Pharmaceutical segment at $62.58 billion dwarfing GMPD at $3.19 billion, so overall results hinge on drug distribution volume and the newly renewed CVS relationship. The balance sheet shows negative shareholders' equity (ROE of -59.45%, debt-to-equity of -3.45) and a current ratio of 0.88, artifacts of buybacks but still a constraint on flexibility if supplier terms or receivables collection deteriorate. Earnings volatility is real: gross margin has ranged from 3.38% in Q2 2026 to 4.30% in Q4 2026, and the stock previously fell sharply when revenue missed despite an earnings beat and raised outlook.
Market and competitive risks are dominated by valuation compression: the trailing PE of 32.68x sits in the upper portion of a historical range that ran from the low teens to the 40s, and the PEG of 2.68 leaves little margin for error if growth slows. The stock trades at 17.58x EV/EBITDA, a premium to the historical distribution-sector norm, and with the average target of $294.87 only ~4.9% above the current $281.10, the sell-side sees limited further upside. Competition among the big three wholesalers — Cencora and McKesson, which together with CAH hold over 90% of the U.S. market — plus Cencora's own raised specialty-driven EPS outlook, means share shifts and generic pricing pressure are constant threats. Regulatory and macro exposure includes drug-pricing policy and IRA-related reimbursement changes, though CAH's beta of 0.521 means broad market moves matter less than sector-specific headlines; the recent divergence from a weak tape (SPY down 2.26% over one month versus CAH up 13.47%) cuts both ways if sentiment reverses.
The worst-case scenario is a revenue miss combined with generic deflation that compresses the multiple back toward the low end of its historical band: a quarterly top-line shortfall triggers analyst downgrades, the forward PE de-rates from 19.55x toward the mid-teens, and the stock retraces toward the $260 analyst low target, roughly -7.5% from $281.10. A deeper drawdown to the $250-$254 consolidation floor would be about -10%, and a full reversion to the 52-week low of $180.45 would represent roughly -36% — consistent with the stock's historical max drawdown of -20.61% being exceeded in a genuine growth scare. The most damaging chain is CVS contract execution issues or specialty growth stalling below the 8-11% guide, which would simultaneously hit earnings estimates and the re-rating narrative that justified the premium multiple.
FAQ
Ranked by severity: first, margin fragility — a 1.12% operating margin and 3.85% gross margin mean a modest generic-pricing concession or mix shift can erase a large share of profit, and gross margin has already swung from 3.38% in Q2 2026 to 4.30% in Q4 2026. Second, revenue-miss sensitivity — the stock previously fell sharply when quarterly revenue fell short of expectations despite an earnings beat and raised outlook, and with only ~4.9% upside to the $294.87 average target, a single top-line disappointment could trigger downgrades and a de-rating from 19.55x forward toward the mid-teens. Third, competitive pressure — Cencora's raised specialty-driven FY2026 EPS outlook signals share gains among the big three wholesalers that control over 90% of the U.S. market, and generic deflation is a structural headwind. Fourth, balance-sheet optics and policy — negative shareholders' equity (ROE -59.45%, debt-to-equity -3.45) and a 0.88 current ratio limit flexibility if supplier terms tighten, while IRA-related reimbursement changes and drug-pricing policy could pressure distribution economics; beta of 0.521 means broad market risk is secondary to these sector-specific threats.
The 12-month outlook is split into three scenarios: a 55% base case targeting $285-$305, a 25% bull case targeting $310-$330, and a 20% bear case targeting $250-$265. The base case assumes revenue growth sustains near 5.47%, gross margin holds in the 3.8-4.0% band, and forward EPS of $20.68 is met, keeping the forward PE near 19.5x as the stock grinds toward the $294.87 average target and consolidates around the $286.29 high. The bull case requires specialty mix to push Pharma segment profit growth above the 8-11% guide, estimate revisions toward the $21.50 high EPS, and multiple expansion toward the mid-20s forward PE, reaching the $330 analyst high. The bear case is a revenue shortfall plus generic deflation that compresses the multiple toward the mid-teens and retraces the stock to the $250-$254 floor and $260 analyst low. The base case is most likely because the raised guidance and CVS renewal are already secured, but the modest ~4.9% implied upside means the forecast is for consolidation rather than a repeat of the 36.42% one-year gain.
The answer depends on which multiple you weight, but the fairest read is fairly valued to modestly rich. The trailing PE of 32.68x sits in the upper portion of a historical range that ran from the low teens to the 40s, well above the ~16-18x seen in 2024 and early 2025, and the PEG of 2.68 means investors are paying more than 2.5x growth for the earnings stream. However, the forward PE of 19.55x on consensus EPS of $20.68 is moderate for a business guiding 8-11% Pharma segment profit growth, and price-to-sales of 0.22x is near the low end of its historical 0.30-0.88x range — so the premium is earnings-driven rather than sales-multiple inflation. At 17.58x EV/EBITDA, CAH trades at a premium to the historical distribution-sector norm, implying the market expects specialty growth and CVS execution to continue. The market is not pricing perfection, but it is pricing optimism: further re-rating requires forward EPS delivery and specialty mix acceleration, while any deceleration would compress the multiple toward the mid-teens and the $260 bear target.
From a pure risk/reward standpoint, CAH is a good business at a mediocre entry point: at $281.10 it offers only about +4.9% upside to the $294.87 average analyst target while sitting 1.8% below its $286.29 52-week high, so the near-term payoff is thin relative to the downside toward the $260 analyst low (-7.5%) or the $250-$254 consolidation floor (-10%). The fundamentals are genuinely strong — 26% EPS growth on 5.47% revenue growth, a raised fiscal 2027 outlook, a long-term CVS renewal, and $4.90 billion of TTM free cash flow — and the 14 Buy / 3 Hold / 0 Sell consensus with a 1.53 recommendation mean confirms durable conviction. The 19.55x forward PE on $20.68 consensus EPS is defensible, but the 32.68x trailing PE and 2.68 PEG leave little cushion for a revenue miss against a 1.12% operating margin. It is a good buy for patient, low-beta-oriented investors willing to accumulate on a pullback into the $250-$254 zone (roughly 15-17x forward EPS), and a poor chase for anyone buying at the high after a 44% six-month run.
CAH is better suited to a long-term hold than a short-term trade, though the entry timing argues for patience. The business is a mature, low-beta (0.521) compounder with visible earnings — management guides 8-11% Pharma segment profit growth for fiscal 2027, consensus EPS is $20.68, and $4.90 billion of TTM free cash flow supports a growing dividend (0.88% yield, 28.6% payout) and $500 million quarterly buybacks that shrink the share count from 238 million to 232 million. That cash-return profile and oligopoly structure reward multi-year ownership rather than momentum chasing, and the stock's 36.42% one-year gain with +24.15% relative strength versus SPY shows the market has already recognized the re-rating. Short-term traders face elevated consolidation risk after a 13.47% one-month and 44.01% six-month run into the $286.29 resistance, with the $250-$254 floor as the key stop level. A reasonable minimum holding period is 12-18 months — long enough to capture at least two more quarterly prints and the fiscal 2027 guidance cycle — with new capital best deployed on a pullback toward $250-$254 rather than at current levels.

